| $385M | ||
| $350M | ||
| $215M | ||
| $82M | ||
| $76M | ||
| $62M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.
Over the last 12 months, insiders at GT Biopharma, Inc. have bought $0 and sold $0 worth of GT Biopharma, Inc. stock.
On average, over the past 5 years, insiders at GT Biopharma, Inc. have bought $50,000 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 50,000 shares for transaction amount of $25,000 was made by Breen Michael Martin (Executive Chairman/Interim CEO) on 2023‑04‑11.
| 2023-04-11 | Breen Michael Martin | Executive Chairman/Interim CEO | 50,000 0.123% | $0.50 | $25,000 | -51.54% | ||
| 2023-04-06 | Ohri Manu | CFO & Secretary | 50,000 0.139% | $0.50 | $25,000 | -44.78% | ||
| 2020-12-22 | Sale | Weldon Steven W | 47,978 0.0139% | $0.40 | $19,191 | -7.75% | ||
| 2020-12-22 | Wendel Bruce | 1,815 0.0116% | $8.84 | $16,037 | -7.75% | |||
| 2020-12-21 | Sale | Weldon Steven W | 135,722 0.0465% | $0.32 | $43,645 | +36.27% | ||
| 2020-12-18 | Sale | Weldon Steven W | 50,000 0.018% | $0.30 | $15,000 | +53.68% | ||
| 2020-12-17 | Sale | Weldon Steven W | 100,000 0.0357% | $0.30 | $30,500 | +49.56% | ||
| 2020-12-16 | Sale | Weldon Steven W | 50,000 0.0184% | $0.30 | $15,000 | +57.16% | ||
| 2020-12-15 | Sale | Weldon Steven W | 150,000 0.0538% | $0.31 | $46,000 | +49.46% | ||
| 2020-12-14 | Sale | Weldon Steven W | 146,300 0.0524% | $0.29 | $41,927 | +59.77% | ||
| 2020-12-11 | Sale | Weldon Steven W | 100,000 0.0342% | $0.26 | $25,500 | +71.90% | ||
| 2020-11-16 | Wendel Bruce | 3,268 0.0201% | $3.14 | $10,262 | +150.45% | |||
| 2020-06-02 | Sale | Cataldo Tony | CEO | 4.23M 0.0294% | $0.00 | $4,234 | +15.02% | |
| 2020-05-13 | Sale | Weldon Steven W | CFO | 2.27M 0.0175% | $0.00 | $2,270 | +17.36% | |
| 2019-02-06 | Sale | Cataldo Tony | director | 800,000 0.0025% | $0.00 | $800 | -68.50% | |
| 2019-02-01 | Sale | Urbanski Raymond W. | CEO | 176,980 0.0005% | $0.00 | $177 | -69.87% | |
| 2010-12-27 | Sale | Theorem Group, LLC | 10 percent owner | 360,100 0.0475% | $0.13 | $47,209 | ||
| 2010-12-27 | Sale | DUBE ANSHUMAN | 360,100 0.0475% | $0.13 | $47,209 | |||
| 2010-12-23 | Sale | Theorem Group, LLC | 10 percent owner | 339,900 0.0445% | $0.13 | $44,187 | ||
| 2010-12-23 | Sale | DUBE ANSHUMAN | 339,900 0.0445% | $0.13 | $44,187 |
| Cataldo Tony | CEO | 6500000 61.1946% | $3.05M | 0 | 2 | |
| Weldon Steven W | 3720000 35.0222% | $1.75M | 0 | 9 | ||
| Urbanski Raymond W. | CEO | 1351918 12.7277% | $634,455.12 | 0 | 1 | |
| Post Gary M | 900000 8.4731% | $422,370.00 | 0 | 5 | ||
| Breen Michael Martin | Executive Chairman/Interim CEO | 656218 6.178% | $307,963.11 | 1 | 0 | <0.0001% |
| Ohri Manu | CFO & Secretary | 50000 0.4707% | $23,465.00 | 1 | 0 | <0.0001% |
| Wendel Bruce | 5083 0.0479% | $2,385.45 | 2 | 0 | +71.35% | |
| DUBE ANSHUMAN | 0 0% | $0 | 0 | 2 | ||
| Theorem Group, LLC | 10 percent owner | 0 0% | $0 | 0 | 2 |
$53,490,060 | 55 | 19.35% | $3.28M | |
$13,664,154 | 40 | -70.35% | $6.22M | |
$1,138,733 | 28 | -4.94% | $3.34M | |
$29,635,355 | 27 | 9.05% | $5.68M | |
$1,039,491 | 21 | -11.76% | $6.84M | |
$337,688 | 19 | -33.30% | $2.36M | |
$742,412 | 14 | -50.36% | $5.93M | |
$684,058 | 11 | -57.59% | $5.1M | |
$405,510 | 11 | -46.23% | $6.41M | |
$389,864 | 11 | 12.52% | $2.51M | |
$105,917 | 11 | -28.06% | $2.42M | |
$18,269 | 10 | -21.15% | $2.61M | |
$8,971,546 | 8 | 6.18% | $5.37M | |
$159,974 | 7 | -18.60% | $6.45M | |
$149,778 | 4 | -45.16% | $3.24M | |
GT Biopharma, Inc. (GTBP) | $76,299 | 4 | 11.60% | $4.98M |
$1,057,000 | 3 | 5.27% | $6.54M | |
$4,423 | 2 | 3.27% | $4.85M | |
$37,000 | 1 | 79.42% | $3.75M |
| Increased Positions | 25 | +80.65% | 360,821 | +96.42% |
| Decreased Positions | 13 | -41.94% | 252,027 | -67.35% |
| New Positions | 22 | New | 309,084 | New |
| Sold Out Positions | 5 | Sold Out | 154,059 | Sold Out |
| Total Postitions | 43 | +38.71% | 483,011 | +29.07% |
| Drw Securities, Llc | $116.00 | 1.29% | 142,380 | +142,380 | New | 2025-09-30 |
| Bank Of Montreal /Can/ | $76.00 | 0.84% | 92,530 | 0 | 0% | 2025-09-30 |
| Citadel Advisors Llc | $32.00 | 0.36% | 39,633 | +39,633 | New | 2025-09-30 |
| Geode Capital Management, Llc | $20.00 | 0.22% | 23,966 | +129 | +0.54% | 2025-09-30 |
| Two Sigma Securities, Llc | $14.00 | 0.16% | 17,065 | +17,065 | New | 2025-09-30 |
| Morgan Stanley | $11.00 | 0.13% | 14,015 | +10,000 | +249.07% | 2025-09-30 |
| Vanguard Group Inc | $9.00 | 0.1% | 10,504 | 0 | 0% | 2025-09-30 |
| Wells Fargo & Company/Mn | $8.00 | 0.09% | 10,012 | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $8.00 | 0.09% | 9,737 | 0 | 0% | 2025-09-30 |
| Osaic Holdings, Inc. | $4.00 | 0.05% | 5,073 | -6,383 | -55.72% | 2025-09-30 |